Organo-Consulting
Bridging Business & Science in the Preclinical & Discovery Industries
Working in
synergy with
Services
​I offer business development and strategic consulting services to life science companies operating in the fast-evolving preclinical & discovery markets, helping them identify emerging opportunities and generate lasting value.
Product Development Strategy & Tech Assessment
Effective planning for product development to gain a competitive edge and maximize value
-
Advisory and guidance for new product & service development/ prioritization
-
Evaluation of scientific and business potential for R&D, M&A
Strategic
Marketing
Enhance your business capabilities and efficiency by refining your market positioning:
-
Market and needs analysis, customer targeting (STP)
-
Identification of market gaps, opportunities, and competitive landscape
-
Development of go-to-market & exit strategies, business plan
Business Development
Generate value and turn opportunities & leads into revenue
-
Lead generation and customer acquisition, content creation to drive brand awareness
-
Scouting and identifying partnership opportunities
-
EU grant & pharma call applications & strategy
Why choosing Organo-Consulting
Time & cost-saving
Consider both scientific, business, and strategic perspectives for comprehensive and accurate analysis.
Solid knowledge
Eight years experience in the NAMs deep tech industry
Personalized approach
Highlighting the uniqueness of your business to stand out from your competitors
Proven track record
-
Successful exit of the company Neurix
-
Led Finnadvance / AKITA to achieve growing & repeated sales
Dual business & scientific background
PhD and eMBA with 8 years of experience as CSO, managing both R&D and business development jointly
Customers
“Working with Organo-Consulting was a real asset for DBM Medix. Their market analysis gave us a clear and structured view of the European microfluidics landscape, especially the IVD and organ-on-chip sectors. The insights were well researched, actionable, and tailored to our business realities. This helped us refine our strategy and better understand how to approach the European market.”
Anuthasan Balasingam, business developper at DBM Medix
Partners
About Organo-Consulting
Organo-Consulting is the business entity under which I – Sébastien Mosser – offer my freelance consulting services.
After I completed my PhD in neuroscience at EPFL (Switzerland), I dove into biotech entrepreneurship. I felt a mix of wonder, inspiration and disappointment when discovering the long and complex path from invention to product, then from product to revenue generation. I learned a lot from the failure of my first entrepreneurial adventure about the importance of understanding precise market needs and dynamics.
These insights have been valuable for the past 8 years working in the NAM deep tech industry. I worked as the chief scientific officer of the brain-on-chip startup Neurix (successful exit) and the MPS company Finnadvance (generating repeated & growing sales), managing R&D and business development simultaneously. I strengthened my business experience with a eMBA degree jointly offered by Helbus (Finland) and Northampton (UK) universities, combining uniting scientific knowledge with business strategy.
​
In both roles, I conducted market analyses to guide the development of deep tech products, ensuring optimal market fit and strategic brand positioning. I also led collaborations with biotech companies, pharmaceutical firms, and academic laboratories and co-authored 12 scientific publications.
Contact
Any question / inquiry? Feel free to reach out, and I'll get back to you promptly.
Increasing complexity of the preclinical & discovery life science markets
​​
The use of cell-based in vitro tests is essential for the development of therapies. These tests have significant
​
The therapy development journey starts with non-clinical phases (discovery & preclinical) to achieve therapy delivery, safety and efficacy prior to clinical phases in human. This field is rapidly evolving through recent technological innovations aiming at better prediction of clinical trial outcome, offering fail-fast / learn fast approaches.
These innovations are converging into new approach methodologies (NAMs) that offer enhance capabilities for modeling human physiology and diseases. Their implementation is stimulated by significant investments and regulatory incentives both in EU and US markets. The NAMs mostly regroup:
-
Microphysiological systems (MPS)
- 3D cell culture (organoids / spheroids)
- Microfluidics
- Co-culture models
- Bioprinting
-
In silico modeling & machine learning
-
Omics and system biology approaches
-
In chemico / cell-free assay
​
These innovations present both opportunities and threats, impacting the competitiveness of all stakeholders in the value chain: therapy-developing companies (APIs, biologicals, formulations), biotechs developing preclinical & discovery tests, service providers CROs /CDMOs as well as manufacturers (Lab-on-chip, microfluidics).
Organo-consulting is a specialized business development and strategic consulting service designed to help companies navigate and generate value in the fast-evolving preclinical & discovery markets. I bring a dual business (eMBA) and scientific (PhD) knowledge with 8 years’ experience in the NAMs deep tech industry. Over the past 3 years I have supported a wide range of clients including big companies, SMEs as well as early startups. I look forward to learning more about your company, project or vision!